|
Aug 5
|
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
|
|
Jul 31
|
KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight
|
|
Jul 25
|
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
|
|
Jul 18
|
Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors
|
|
Jul 16
|
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating
|
|
Jul 10
|
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Jul 9
|
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
|
|
May 29
|
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
|
|
May 6
|
Cogent Biosciences Reports First Quarter 2025 Financial Results
|
|
May 5
|
Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
|
|
Apr 16
|
Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?
|
|
Feb 10
|
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
|
|
Sep 3
|
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
|
|
Jun 14
|
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
|
|
May 13
|
We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
|
|
May 7
|
Cogent Biosciences Reports First Quarter 2024 Financial Results
|
|
Apr 9
|
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
|
|
Feb 14
|
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
|
|
Jan 9
|
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
|
|
Jan 2
|
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
|